Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02735980 · ClinicalTrials.gov registry record · Phase 2
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 study of Small-cell Lung Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 20
- Study locations
NCT02735980: Completed Phase 2 study of Small-cell Lung Cancer, sponsored by Eli Lilly and Company.
NCT02735980 is a Phase 2 study of Small-cell Lung Cancer that has completed, run by Eli Lilly and Company. The registered enrollment target is 133 participants, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02735980, a Phase 2 study of Small-cell Lung Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life.
Primary Outcome
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of n
Conditions Studied
Interventions
- DRUG Prexasertib
Study Locations (20)
Other
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Besançon
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Lille
- "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician." - Montpellier
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Vantoux
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Halle
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Athens
Tennessee
- Chattanooga Oncology Hematology Associates - Chattanooga
- Sarah Cannon Cancer Center - Nashville
- Tennessee Oncology PLLC - Nashville
- Vanderbilt University Medical Center - Nashville
Florida
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists and Research Institute - St. Petersburg
Texas
- The Center for Cancer and Blood Disorders - Fort Worth
- University of Texas MD Anderson Cancer Center - Houston
Arkansas
- Highlands Oncology Group - Fayetteville
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Massachusetts
- Massachusetts General Hospital - Danvers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2019-02-12 |
| Phase | Phase 2 |
What the finished NCT02735980 record still lists
NCT02735980 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Prexasertib is the first listed.
NCT02735980 names 20 study sites across 10 states, led by Other, Tennessee, Florida.
Frequently Asked Questions
What is clinical trial NCT02735980 about?
NCT02735980 is a clinical study titled "A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer". The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the associ...
What is the current status of trial NCT02735980?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2016-05-11. Estimated completion is 2019-02-12.
What conditions does trial NCT02735980 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT02735980?
The interventions under investigation include: Prexasertib (DRUG).
Who is sponsoring clinical trial NCT02735980?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02735980 being conducted?
This trial has 20 study locations across Arkansas, Connecticut, District of Columbia, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02735980's enrollment target sits among peer trials
133 31st of 79 higher than 49 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Trilaciclib and Lurbinectidin
RECRUITING · Phase 2
-
Phase 2 Study of Fingolimod in Lung Cancers
RECRUITING · Phase 2
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI